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Abstract: Short-chain quinones (SCQs) have been identified as potential drug candidates against
mitochondrial dysfunction, which largely depends on the reversible redox characteristics of the active
quinone core. We recently identified 11 naphthoquinone derivatives, 1–11, from a library of SCQs that
demonstrated enhanced cytoprotection and improved metabolic stability compared to the clinically
used benzoquinone idebenone. Since the toxicity properties of our promising SCQs were unknown,
this study developed multiplex methods and generated detailed toxicity profiles from 11 endpoint
measurements using the human hepatocarcinoma cell line HepG2. Overall, the toxicity profiles were
largely comparable across different assays, with simple standard assays showing increased sensitivity
compared to commercial toxicity assays. Within the 11 naphthoquinones tested, the L-phenylalanine
derivative 4 consistently demonstrated the lowest toxicity across all assays. The results of this study
not only provide useful information about the toxicity features of SCQs but will also enable the
progression of the most promising drug candidates towards their clinical use.
Keywords: mitochondria; short-chain quinone; idebenone; cytotoxicity
1. Introduction
Mitochondrial dysfunction causes a large number of diverse mitochondrial diseases, such as
Friedreich’s ataxia (FA) [1], Leigh syndrome (LS) [2], mitochondrial encephalopathy, lactic acidosis,
stroke-like episodes syndrome (MELAS) [3], maternally inherited diabetes and deafness (MIDD) [4],
Leber’s hereditary optic neuropathy (LHON) [5], and dominant optic atrophy (DOA) [6].
Mitochondrial dysfunction is also described for many common inflammatory (i.e., ulcerative colitis) [7],
neurodegenerative (i.e., Alzheimer’s disease, Parkinson’s disease, glaucoma, age-related macular
degeneration) [8], neuromuscular (i.e., Duchenne muscular dystrophy (DMD), multiple sclerosis) [9],
and metabolic disorders (i.e., diabetes, obesity) [10]. However, despite the high incidence of disorders
with a mitochondrial pathology, there is a scarcity of approved drugs that aim to directly protect
against mitochondrial dysfunction. This significant unmet medical need requires new drug candidates
that could be of benefit to a multitude of indications. Potential drug candidates that protect against
mitochondrial dysfunction include short-chain quinones (SCQs), which possess reversible redox
characteristics due to their quinone core [11–13]. Several SCQs are currently in clinical development.
The vitamin E derivative vatiquinone (EPI-743/PTC-743), an antioxidant that targets NAD(P)H:quinone
oxidoreductase 1 (NQO1), was initially developed for FA (Phase II, NCT01962363, 3 × 400 mg for
18 months, with reported improved neurological functions) [14] and LS (Phase II, NCT01721733,
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3 × 100 mg for 6 months, with reported improved movement) [15], and was recently acquired by
PTC Therapeutics. Another vitamin E derivative, sonlicromanol (KH176, Khondrion), a reactive
oxygen species (ROS) modulator, is in development for MELAS and MIDD (Phase II, NCT02909400,
2 × 100 mg for 28 days, with reported tolerance and safety) [16], LS and LHON (Phase I, NCT02544217,
800 mg for 7 days, with reported tolerance) [17]. The only drug currently available to patients is
benzoquinone idebenone, which protects against vision loss and has even restored visual acuity in
some LHON patients [18]. Especially for the subgroup of recently affected patients, idebenone has
been shown to improve visual acuity and color vision [19,20]. A recent report also suggested that
idebenone ameliorated mitochondrial complex I deficiency and stabilized/restored visual acuity in
patients with DOA [6,21]. In contrast, earlier phase III clinical trials (NCT00905268; NCT00537680)
in FA patients were unable to demonstrate therapeutic efficacy for idebenone [22]. Based on its
cytoprotective activity under the conditions of mitochondrial dysfunction (hereafter referred to as
mito-protection), idebenone was suggested for a wide range of disorders. Contrary to the widespread
belief that idebenone is a CoQ10 analogue and acts as antioxidant, recent reports paint a very different
picture: idebenone was reported to directly bind and inhibit p52Shc at nanomolar concentration [23],
but also acts as PPARα/γ agonist, albeit at higher concentrations [24]. Finally, idebenone activates
the expression of Lin28A in vivo, which was shown to be required for retinal neuroprotection and
recovery of vision [25]. Although it is unclear at present if these activities of idebenone are causally
connected, they all converge to activate Akt signalling, which alters metabolic functions, increases
insulin sensitivity, increases mitochondrial function and stress resistance, and induces tissue repair.
Although idebenone has consistently demonstrated very good safety in healthy subjects (2250 mg/day,
14 days) [26] and different patient groups (LHON patients: 900 mg/day, 24 weeks [18]; DMD patients:
900 mg/day, 52 weeks [27]), its efficacy is restricted by its limited absorption, a rapid first-pass effect [28],
and its reliance on a single reductase for its bioactivation [12,13].
We recently reported the design and synthesis of a library of > 148 novel short-chain
naphthoquinone derivatives [29] to overcome the known limitations of idebenone, such as limited
bioactivation and rapid metabolic inactivation. From this library, 11 compounds (1–11, Table 1) showed
significantly improved cytoprotective activity under the conditions of mitochondrial dysfunction
and increased metabolic stability in vitro compared to idebenone [29,30]. The current study aimed
to compare the in vitro toxicity of these 11 compounds against idebenone to identify possible drug
candidates that could be progressed towards clinical development.
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Table 1. Chemical structure, physical properties, in vitro efficacy, and stability of the benzoquinone idebenone and 11 novel naphthoquinone derivatives.
Compound Structure N R Formula
Molecular
Weight
(g/mol)
LogP 1 LogD 2
In Vitro Cytoprotection 3
In Vitro Metabolic
Stability 4
% p-Value % p-Value
Idebenone
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Ideb none - - C19H30O5 338.4 1.24 3.57 66.2 ± 
12.0 
- 
27.3 ± 
3.9 
- 
1 
(UTAS#81) 
2 
C23H23NO4 377.4 2.24 2.81 
83.8 ± 
19.9 
0.191 
92.6 ± 
16.9 
<0.001 
2 
(UTAS#80) 
C23H23NO4 377.4 2.24 2.81 
87.6 ± 
19.7 
0.025 
96.6 ± 
11.1 
<0.001 
3 
(UTAS#62) 
C24H25NO4 391.5 2.52 3.10 
93.1 ± 
13.7 
<0.001 
84.0 ± 
15.5 
<0.001 
4 
(UTAS#37) 
2 C24H23NO5 405.4 2.48 0.12 
100.3 
± 17.3 
<0.001 
96.0 ± 
7.5 
<0.001 
5 
(UTAS#72) 
3 C25H25NO5 419.5 2.90 0.74 
90.7 ± 
15.6 
0.146 
91.4 ± 
0.8 
<0.001 
6 
(UTAS#74) 
2 
 
C23H23NO4 377.4 2.67 3.43 
91.7 ± 
15.6 
0.101 
45.7 ± 
2.9 
0.034 
7 
(UTAS#88) 
3 C24H25NO4 391.5 3.09 3.87 
91.8 ± 
9.8 
0.097 
60.3 ± 
1.7 
<0.001 
8 
(UTAS#54) 
2 
C21H25NO5 371.4 2.04 0.26 
98.7 ± 
10.9 
0.004 
84.3 ± 
9.2 
<0.001 
9 
(UTAS#77) 
C25H27NO5 421.5 2.80 3.41 
95.9 ± 
19.4 
0.017 
58.3 ± 
11.0 
<0.001 
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- - C19H30O5 338.4 1.24 3.57 66.2 ± 12.0 - 27.3 ± 3.9 -
1
(UTAS#81)
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(UTAS#77)
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Table 1. Chemical structure, physical properties, in vitro efficacy, and stability of the benzoquinone idebenone and 11 novel naphthoquinone derivatives. 
Compound Structure N R Formula 
Mol cular 
Weight  
(g/mol) 
LogP 1 LogD 2 
In Vitro 
Cyt protection 3 
In Vitro 
Metabolic 
Stability 4 
% p-Value % p-Value
Idebenone - - C19H30O5 338.4 1.24 3.57 66.2 ± 
12.0 
- 
27.3 ± 
3.9 
- 
1 
(UTAS#81) 
2 
C23H23NO4 377.4 2.24 2.81 
83.8 ± 
19.9 
0.191 
92.6 ± 
16.9 
<0.001 
2 
(UTAS#80) 
C23H23NO4 377.4 2.24 2.81 
87.6 ± 
19.7 
0.025 
96.6 ± 
11.1 
<0.001 
3 
(UTAS#62) 
C24H25NO4 391.5 2.52 3.10 
93.1 ± 
13.7 
<0.001 
84.0 ± 
15.5 
<0.001 
4 
(UTAS#37) 
2 C24H23NO5 405.4 2.48 0.12 
100.3 
± 17.3 
<0.001 
96.0 ± 
7 5 
<0.001 
5 
(UTAS#72) 
3 C25H25NO5 419.5 2.90 0.74 
90.7 ± 
15.6 
0. 46 
91.4 ± 
0 8 
<0.00  
6 
(UTAS#74) 
2 
 
C23H23NO4 377.4 2.67 3.43 
9 .7 ± 
15.6 
0.101 
45.7 ± 
2.9 
0.034 
7 
(UTAS#88) 
3 C24H25NO4 391.5 3.09 3.87 
91.8 ± 
9.8 
0.097 
60.3 ± 
1.7 
<0.001 
8 
(UTAS#54) 
2 
C21H25NO5 371.4 2.04 0.26 
98.7 ± 
10.9 
0.004 
84.3 ± 
9.2 
<0.001 
9 
(UTAS#77) 
C25H27NO5 421.5 2.80 3.41 
95.9 ± 
19.4 
0.017 
58.3 ± 
11.0 
<0.001 
O
O
O
O
OH
O
O
NH
O
n
R
OH
OH
OH
OH
O
OH
O
OH
O
O
C25H27NO5 421.5 2.80 3.41 95.9 19.4 0.017 58.3 ± 11.0 <0.001
10
(UTAS#61)
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-  C20H23NO4 341.4 1.06 1.71 
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0.002 
78.9 ± 
7.4 
<0.001 
11 
(UTAS#43) -  
C20H21NO5 355.4 1.02 -1.32 
92.7 ± 
7.6 
0.018 
67.2 ± 
2.3 
<0.001 
1 LogP was predicted using ChemDraw Professional software (version 16.0, PerkinElmer, MA, USA). 2 LogD was predicted using MarvinView software (version 
19.25, ChemAxon, Budapest, Hungary). 3 In vitro cytoprotection of HepG2 by 10 μM SCQs against rotenone-induced mitochondrial complex I dysfunction. 
Cytoprotection was calculated as a relative percentage of cell survival compared to untreated cells (26.9 ± 7.9%). Data was expressed as mean ± standard deviation 
(SD) [29]. 4 In vitro metabolic stability of 40 μM SCQs over 6 h on HepG2. Stability was calculated as percentage compounds found remaining after 6 h. Data was 
expressed as mean ± SD [30]. 
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Budapest, Hungary). 3 In vitro cytoprotection of HepG2 by 10 µM SCQs against rotenone-induced mitoc ondrial complex I dysfunction. Cytoprotection was calculated as a relative
percentage of cell survival compared to untreated cells (26.9 ± 7.9%). Data was expressed as mean ± standard deviation (SD) [29]. 4 In vitro metabolic stability of 40 µM SCQs over 6 h on
HepG2. Stability was calculated as percentage compounds found remaining after 6 h. Data was expressed as mean ± SD [30].
Pharmaceuticals 2020, 13, 0184 4 of 20
2. Results
2.1. WST-1 Assay
This study aimed to assess the in vitro toxicity of our test compounds in the hepatic cell line HepG2
across a range of assays to measure different toxicity-related endpoints including metabolic toxicity,
membrane integrity, mitochondrial toxicity, mechanisms of cell death, DNA damage, and transformation
potential. When cellular NAD(P)H synthesis as a surrogate marker for cellular metabolism was
measured using the widely employed WST-1 dye, the reference compound idebenone significantly
reduced WST-1 absorption from 150 µM onwards (p < 0.001; Figure 1a). In comparison, most test
compounds already reduced absorption from 25 µM (3 and 8), 50 µM (1, 2, and 9–11), and 75 µM
(6 and 7) onwards, respectively (p < 0.033; see Table S1 for full dataset). In contrast, compared to
the untreated control cells, a significant reduction of WST-1 absorption by compounds 4 and 5 was
only observed from 175 µM onwards (p < 0.002) and 200 µM (p < 0.001), respectively. Compared to
idebenone, compounds 4 and 5 from 150 µM onwards reduced WST-1 absorption significantly less
(p < 0.001).Pharmaceuticals 2020, 13, x FOR PEER REVIEW 6 of 22 
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Figure 1. Effect of test compounds on metabolic toxicity. Cells were exposed to reference and test
compounds (0–200 µM) for 24 h before (a) WST-1 absorption; (b) ATP levels; (c) protein contents
were quantified. Data represents mean ± SEM of 3 independent experiments with 6 parallel wells per
experiment. Two-way ANOVA was performed to compare test concentrations against the non-treated
control: *** p < 0.001, ** p < 0.002, * p < 0.033. Full datasets shown in Tables S1–S3.
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2.2. ATP Levels
As another marker of metabolic toxicity, cellular ATP levels were assessed in the absence or
presence of the reference or test compounds. The reference compound idebenone significantly reduced
ATP levels from 125 µM onwards (p < 0.001; Figure 1b, Table S2). Similar to the WST-1 results,
a significant reduction was only observed at 200 µM by compound 4 and from 150 µM onwards
by compound 5 (p < 0.033), respectively, while other compounds already significantly reduced ATP
levels from 50–75 µM compared to the untreated cells (p < 0.033; Table S1). Compared to idebenone,
compounds 4 and 5 showed a significantly lower effect on ATP levels (p < 0.001) from 150 and 125 µM
onwards, respectively (Figure 1b; Table S2).
2.3. Protein Levels
Since our test compounds had similar effects on both ATP levels and the conversion of WST-1 dye,
we assessed the levels of protein per well as a surrogate marker for cellular content. The reference
compound idebenone significantly reduced protein levels from 100 µM onwards (p < 0.001; Figure 1c).
Of 11 tested compounds, 4 and 5 significantly reduced protein levels from 100 µM onwards (p < 0.002),
while significant reductions by the other compounds were already evident at 50–75 µM (p < 0.001;
Table S3). At higher concentrations from 125 µM onwards, compounds 4 and 5 affected protein levels
significantly less than idebenone (p < 0.001).
2.4. Membrane Integrity
Propidium iodide (PI) staining was employed as a measurement of impaired membrane integrity.
The reference compound idebenone significantly increased PI incorporation from 100 µM onwards
(p < 0.033; Figure 2a). Of 11 tested compounds, 4 did not increase PI incorporation significantly at
all tested concentrations, while 2 compounds increased from 150 µM (5, p < 0.033; 11, p < 0.001),
1 compound from 125 µM (8, p < 0.001), 1 compound from 100 µM (7, p < 0.001), 4 compounds from
75 µM (3, 6, 9 and 10, p < 0.001), and 2 compounds from 50 µM onwards (1, p < 0.033; 2, p < 0.001;
Table S1). Compared to idebenone, the observed effects by compounds 4, 5, and 11 was significantly
lower from 100 µM onwards, at 125–150 µM, and at 100–125 µM, respectively (p < 0.033; Table S4),
while the effect by compound 8 was not statistically significant, and the effects by the other derivatives
were significantly higher between 50 and 200 µM.
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Figure 2. Effect of test compounds on membrane integrity. Cells were exposed to reference or test
compounds (0–200 µM) for 24 h before (a) propidium iodide (PI) incorporation; (b) necrotic-cell protease
activity, and (c) viable-cell protease activity (Multi-Tox Fluor Kit) were assessed. Data represents mean
± SEM from 3 independent experiments with 4 parallel wells per experim nt. Two-way ANOVA was
performed to compare test concentrations against the non-treated control: *** p < 0.001, ** p < 0.002,
* p < 0.033. Full datasets shown in Tables S4–S6. RFU, relative fluorescence units.
2.5. Multi-Tox Fluor Assay
Based on the effects of th test c mpounds on PI stainin , we assessed cell membrane integrity
using a commercially available kit that proposed to simultaneously assess this endpoint and cell
viability. The reference compound idebenone did not significantly increase bis-AAF-R110 fluorescence,
which is indicative of a lack of necrotic-cell protease activity at all test concentrations (Figure 2b). Of the
11 tested compounds, 5 compounds did not significantly increase bis-AAF-R110 fluorescence at any
concentration (1–5), while compound 10 increased fluorescence at 200 µM (p < 0.033), compound 6
increased at 125–150 µM (p < 0.033), and four other compounds increased fluorescence from 125 µM
onwards (7–9 and 11, p < 0 001; Table S5). Compared to the effects of idebenone, no significant
increases by compounds 1–6 were observed, while compound 10 showed significantly higher levels
of bis-AAF-R110 fluorescence at 200 µM (p < 0.033), 3 compounds from 150 µM onwards (8 and 9,
p < 0.002; 11, p < 0.033), and compound 7 from 125 µM onwards (p < 0.033; Table S5), respectively.
While bis-AAF-R 10 measure the activity of the necrosis-associated protease, the protease
substrate GF-AFC is thought to measure live cells with intact plasma membrane. In our test system,
idebenone significantly reduced GF-AFC fluorescence from 75 µM onwards (p < 0.001; Figure 2c,
Table S6). In contrast, a significant reduction by compounds 4, 5, and 11 were only observed from 150,
125, and 175 µM onwards (p < 0.033), respectively. However, the remaining 8 compounds significantly
reduced fluorescence already at 25–50 µM (p < 0.033; Table S6). Compared to id benon , a significantly
lower reduction of fluorescence was detected for compounds 4, 5, and 11 from 75 µM onwards
(p < 0.001, Table S6).
2.6. Mitochondrial Superox de Production
To further assess if the observed toxicity of the test compounds could be attributed to mitochondrial
toxicity, mitochondrial superoxide production was measured. Antimycin A, used as a positive control in
our test system [31], significantly increased the fluorescence of the mitochondrial superoxide indicator
MitoSOX from 25 µM onwards (p < 0.001, Table S7), while idebenone did not increase MitoSOX
fluorescence across all tested concentrations (Figure 3). Of the 11 test compounds, 3 compounds
significantly increased MitoSOX fluorescence to different degrees (5, 200 µM, p < 0.033; 8, ≥100 µM,
p < 0.033; 11, ≥100 µM, p < 0.002), while for the 8 other test compounds no significant increases were
detected. The observed increases by the 3 test compounds (5, 8, and 11) were significantly lower
compared to antimycin A for all concentrations (p < 0.001). Compared to idebenone, compounds 5, 8,
and 11 significantly increased MitoSOX fluorescence from 150 µM (p < 0.033), 75 µM (p < 0.033) and
75 µM (p < 0.002) onwards, respectively (Figure 3).
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Figure 3. Effect of test compounds on it c i e r uction. Cells were exposed to
reference (antimycin A, idebe s ( –200 µ ) for 30 min before mitochondrial
superoxide levels were quantified. at SEM of 3 independent experiments
with 8 parallel wells per experiment. Two-way ANOVA was performed to c mpare est concentra ions
against the n -treated control: *** p < 0.001, ** p < 0.002, * p < 0.033. Full datasets available in Tabl S7.
2.7. Colony Formation
Long-term toxicity was assessed using a standard colony formation assay, where the reference
compound ideben ne significantly re uced colony formation from 10 µM onwards (p < 0.002; Figure 4).
Of the 11 test compounds, compoun s 4 and 5 signific ntly educed colony numbers from 20 µM
(p < 0.001) and 10 µM (p < 0.002) onwar s, respect vely, while all other compounds already showed
a significant reduction in colony numbers at 5 µM (p < 0.001; Table S8). The effects of compounds
4 and 5 were significantly lower across all test concentrations (p < 0.001), compared to the other
test compounds.
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2.8. Nuclear Morphology
The previous results suggest t icity at higher concentrations was mainly
associated with a los of cells ll e brane integrity, which is indicative of reduced
proliferation and/or cell death. i t t i i s sed to si ultaneously quantify nuclei
numbers per field of vision, nuclear size, and fluorescence intensity as markers of pyknosis, respectively.
Using this analysis, the reference compound idebenone, like most test compounds (1–3 and 8–10),
significantly reduced nuclei numbers (p < 0.001) and nuclear size (p < 0.033) and increased nuclear
fluorescence (p < 0.002) at 100 µM (Figure 5). Although 4 compounds (5–7 and 11) significantly reduced
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nuclei numbers (5, p < 0.033; 6, 7, and 11, p < 0.001), no significant changes to the nuclear size or
fluorescence intensity were detected. Compound 4 did not significantly change nuclei number, size,
or fluorescence intensity. Overall, the individual results of this approach appear mostly consistent in
that those compounds which reduce nuclei numbers, also decrease nuclear area and increase nuclear
fluorescence (Figure 5a–c).
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Figure 5. Effect of test co pounds on nuclear count and morphology. Cells were exposed to reference
or test co pounds (100 µM) for 24 h before (a) nuclear count, (b) area, and (c) intensity were
assessed. Exemplary fluorescence images (60 ×magnification) of (d) non-treated (NT) and (e) treated
DAPI-stained nuclei; single cell plots of nuclei either (f) NT or (g) treated with compound 3 are
presented. Compound 3 (e,g) significantly reduced average nuclear count and size, and increased
average fluorescence intensity than NT (d,f). Nuclear RFU was standardized on the average intensity
of NT control nuclei and expressed as fold-change. Data represents mean ± SEM of 8 independent
images per treatment. Two-way ANOVA was performed to compare idebenone or test compounds
against the non-treated control: *** p < 0.001, ** p < 0.002, * p < 0.033.
2.9. DNA a age
Due to the report t pounds [29] and the observed reactive oxygen
species (ROS) production by some compounds, the possibility of oxidative stress-induced DNA damage
was ass ssed (Figure 6). For this purp se, the structurally related naphthoquinone menadio e was
used as a positive control [32]. In our test system, menadione significantly increased the number of
γ-H2AX-positive cells from 20 µM onwards (p < 0.001), while no signs of DNA damage by idebenone
were detected across all the concentrations tested (Figure 6). Of the 11 test compounds, 3 and 4 did not
significantly increase the number of γ-H2AX-positive cells at any concentration, while 2 compounds
increased the number of γ-H2AX-positive cells at 40 µM (10, p < 0.033; 11, p < 0.001), 5 compounds
increased γ-H2AX-positive cells from 30 µM onwards (1, 4, and 9, p < 0.002; 5 and 6, p < 0.033),
1 compound showed an increase from 20 µM (1, p < 0.001), and 1 compound showed an increase from
10 µM onwards (8, p < 0.033). Increased numbers of γ-H2AX-positive cells by 6 compounds (3–5 and
9–11) were significantly lower compared to menadione across all test concentrations (p < 0.033) and no
significant differences were observed between compounds 3, 4, and idebenone (Figure 6).
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Figure 6. Effect of test compounds on DNA damage. Cells were exposed to reference compounds
(menadione, idebenone) or test compounds (0–40 µM) for 4 h before the presence of nuclear γ-H2AX
positive cells was quantified. (a) Exemplary images (60 × magnification) used for quantitation of
γ-H2AX-positive cells using compound 7 as positive treatment and (b) quantitation of results for all
reference and test compounds. Data represent the mean ± SEM of 3 independent experiments with
4 parallel wells per experiment. Overall, >1000 cells were analysed per treatment. Two-way ANOVA
was performed to compare test concentrations against the non-treated control: *** p < 0.001, ** p < 0.002,
* p < 0.033.
2.10. Transformation Potential
Based on the i cti of γ-H2AX, indicative of DNA damage by some test compounds,
their potential to transform substrate-dependent growth of HepG2 cells into substrate-independent
cell growth by DNA mutations was assessed. To quantify transformation potential of our test
compounds, a high throughput variant of the traditional semi-solid agar invasion assay was
employed [33] using resorufin fluorescence as the indicator of cell growth [34]. The mutagenic
compound 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) was used as a positive control [35].
In our test system, PhIP exhibited its reported transformation potential by significantly increasing
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substrate-independent cell growth (p < 0.001, Figure 7), while neither idebenone nor any of the test
compounds significantly increased cell growth at any test concentration. Similar to PhIP (p < 0.001),
all reference and test compounds, except for compound 4, significantly reduced resorufin fluorescence
at 40 µM (p < 0.002) as a consequence of increased compound toxicity. Compared to idebenone, the
reduction of resorufin fluorescence by compound 4 was significantly lower across all test concentrations
(p < 0.002). At 40 µM, compounds 5 and 11 showed significantly lower inhibitory effects compared
to idebenone, whereas all other compounds showed greater inhibition from 10–20 µM onwards
(p < 0.002).
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(PhIP, idebenone) or test compounds (0–40 µ ) f r ft agar before ce l growth under these
condit ons was quantified. SEM of 8 independent wells per treatment.
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*** p < .001, ** p < .002, * p < 0.033.
2.11. Summary of Results
Comparative in vitro toxicities of the test co pounds 1–11 against the reference compound
idebenone are summarized in Table 2.
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Table 2. Summary of the in vitro toxicity of compounds.
Compound
Multiplex Detection
Membrane
Integrity 2
Multi-Tox Fluor Assay
Mitochondrial
Superoxide 2
Colony
Formation 1
Pyknosis
DNA
Damage 2
Transformation
PotentialWST-1 1 ATP 1 Protein 1
Necrotic-Cell
Protease 2
Viable-Cell
Protease 1
Idebenone 151.7 ± 5.9 146.8 ± 14.2 136.8 ± 4.7 ≥100 N 71.1 ± 11.1 N 26.0 ± 5.2 Y N N
1 59.0 ± 2.2 59.0 ± 4.7 59.6 ± 0.6 ≥50 N 55.8 ± 9.1 N 6.2 ± 1.8 Y ≥30 N
2 45.7 ± 1.3 45.5 ± 3.8 52.7 ± 7.1 ≥50 N 50.7 ± 7.1 N 4.8 ± 0.1 Y ≥20 N
3 88.8 ± 8.8 95.4 ± 9.2 66.1 ± 7.2 ≥75 N 54.9 ± 7.6 N 7.1 ± 3.2 Y N N
4 >200 >200 >200 N N >200 N 31.2 ± 10.5 N N N
5 >200 >200 >200 ≥150 N 161.5 ± 15.2 ≥200 20.6 ± 5.9 N ≥30 N
6 69.6 ± 1.8 67.0 ± 4.7 66.3 ± 4.9 ≥75 ≥125 52.0 ± 9.3 N 4.7 ± 1.1 N ≥30 N
7 78.0 ± 5.6 78.2 ± 4.4 60.0 ± 8.3 ≥100 ≥125 56.1 ± 8.2 N 4.2 ± 1.0 N ≥30 N
8 83.1± 3.7 88.8 ± 10.5 80.8 ± 3.3 ≥125 ≥125 155.8 ± 15.7 ≥100 8.1 ± 2.3 Y ≥10 N
9 55.4 ± 6.7 52.3 ± 4.8 57.3 ± 9.2 ≥75 ≥125 49.0 ± 11.8 N 5.6 ± 1.1 Y ≥30 N
10 51.5 ± 9.6 55.9 ± 12.0 61.2 ± 7.7 ≥75 ≥200 57.9 ± 7.8 N 4.8 ± 0.5 Y ≥40 N
11 99.7 ± 5.8 108.0 ± 19.2 91.8 ± 5.1 ≥150 ≥125 >200 ≥100 7.4 ± 1.4 N ≥40 N
1 Data represents half maximal inhibitory concentrations (IC50) ± SD (µM) calculated using GraphPad Prism (version 8.2.1, San Diego, CA, USA). 2 Data represents the lowest observable
concentration (µM) to cause statistically significant effects. Full datasets shown in Tables S1–S8. Y, detected; N, not detected.
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3. Discussion
This study aimed to characterize the in vitro toxicity of the most promising compounds out of a
novel range of cytoprotective and mito-protective short-chain quinones (SCQs) [29,30]. Due to the
redox activity of the quinone moiety [29], this class of compounds is associated with an inherent risk of
producing reactive oxygen species (ROS) [36,37], which could lead to toxicity and cell death at higher
concentrations. In addition, the redox activity of quinones can generate false-positive results in many
standard viability assays such as MTT and WST-1 [38,39]. Similarly, there is good evidence that redox
reactions of SCQs can affect growth factor signalling [23,40] and cell proliferation, which can affect
assays that rely on proliferation such as the colony formation assay. Consequently, the current study
employed several distinct assays to assess different forms of toxicity including metabolic toxicity, loss of
cell membrane integrity, mitochondrial ROS production, long-term toxicity, pyknosis, DNA damage,
and transformation potential.
Based on data of related compounds in pre-clinical animal models and patients, the liver is
expected to be exposed to the highest concentrations of SCQs [26,41]. In addition, some unrelated
compounds have been reported to only show toxicity after metabolic conversion in the liver [42].
Therefore, the present study used a liver-derived cell line to account for this fact. Although HepG2
cells are less metabolically active compared to primary hepatocytes and other cell lines such as
C3A or HepaRG, HepG2 cells are widely employed for in vitro toxicity studies due to their high
phenotypic stability and unlimited availability for robust and reproducible outcomes [43,44]. It must
be acknowledged that this approach cannot exclude tissue-specific toxicities such as neurotoxicity,
so our data can only serve as a first approximation to compare the test compounds against reference
compounds and against each other. Some test compounds have been successfully used in several
animal models of different diseases, in both systemic (oral) and topical (eyedrops) applications over
months, without any overt signs of toxicity (unpublished results). This could indicate that this chemical
class is generally associated with low toxicity, comparable to the reference compound idebenone;
however, this remains to be confirmed experimentally.
When metabolic toxicity was assessed, in general, ATP levels appeared a more sensitive readout
compared to the WST-1 assay for all the compounds tested. This could indicate that the interaction
of the redox active compounds interfered with the conversion of the WST-1 dye [39] or that the
test compounds specifically affect ATP production. Due to this uncertainty, the WST-1 and similar
assays should only be used with great caution when testing compounds with confirmed or suspected
redox activity. Despite the metabolic limitation of HepG2 cells, our data clearly demonstrate the
superior safety profile of the L-phenylalanine derivatives 4 and 5 compared to idebenone to enable
us to progress these candidates in future studies. It is interesting to note that protein content per
well, indicative of cell number, also appeared less sensitive than the measurement of ATP levels.
This supports the idea that the test compounds at higher concentrations affect ATP levels in our test
system while simultaneously leading to cell loss, presumably by a cell death pathway that involves
pyknosis. The subsequent measurement of structural integrity of the cell membrane largely mirrored
the toxicity observed with the ATP assay. Surprisingly, the commercial Multi-Tox Fluor assay displayed
significantly lower sensitivity when measuring membrane integrity compared to a standard propidium
iodide (PI) incorporation assay. The reason for this is not known. While we can only speculate that
compared to simple diffusion and binding kinetics of a dye such as PI, the enzymatic conversion of a
substrate underlies more restrictive conditions, which might be partially impaired under the specific
conditions of our test system. It is interesting to note that the mitochondrial superoxide production did
not correlate with the observed ATP data, which suggests that mitochondrial ROS is not responsible for
the metabolic toxicity, while the observed acute toxicities were replicated by the colony formation assay
that measures long-term toxicity. Overall, the results of the present study consistently demonstrate
that only the two L-phenylalanine derivatives 4 and 5 show comparable or lower levels of toxicity
compared to the reference compound idebenone across most endpoints utilized in this study.
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Since most results in this study could be attributed to cell loss, we assessed structural changes in
nuclear morphology (pyknosis), which is mostly indicative of apoptotic cell death [45]. Surprisingly,
the results of this approach differed significantly from the results of the previous assays. In particular,
the significantly lower induction of pyknosis by several test compounds compared to idebenone
did not correlate with the previous toxicity assays (Table 2). For some compounds, the measured
toxicity did not lead to a significant induction of pyknosis despite profound effects on protein levels,
such as the tyramine derivatives 6 and 7 and the L-proline derivative 11. The molecular reason for
this obvious discrepancy is unclear at present and is subject to ongoing investigations but could
either involve a different form of cell death such as necrosis or a difference in time course. When we
assessed the DNA damaging potential of our test compounds, idebenone did not induce any DNA
damage, while most test compounds showed a dose-dependent induction of DNA damage at higher
concentrations. One exception was the L-phenylalanine derivative 4 that consistently showed low or
absent toxicity throughout most assays. However, the structurally related L-phenylalaninol derivative
3 [30], also showed no significant induction of DNA damage, which was surprising given the consistent
toxicity results from all other assays. Based on the observed DNA damaging activity of some test
compounds, their transformation potential was assessed. The reference compound PhIP increased
transformation only up to 30 µM in our test system, since cytotoxicity at higher concentrations has
been reported [46]. In contrast, the clinically used idebenone [47,48] as well as the test compounds also
did not appear to promote cellular transformation in this test system, but their toxicities were mirrored
in the agar invasion assay in a concentration dependent manner.
Collectively, this study highlights the independence of the toxicity assays used and justifies a
panel of assays to detect the different aspects of toxicity of a class of compounds during early drug
development. The current study indicates that the carboxylic acid derivatives (i.e., 4 and 11) are
significantly less toxic than the corresponding alcohols (i.e., 3 and 10, respectively). One possible
explanation could be that oxidative metabolites of alcohols could show greater toxicity. However,
the reported high metabolic stability of these compounds [30] seems to directly implicate the alcohol
function in their increased toxicity in vitro. Although the current study does not allow any predictions
towards toxicity in vivo, it is important to relate the observed results to expected in vivo concentrations.
At present, achievable plasma or tissue levels for the test compounds are not known. However, for
the chemically related reference compound idebenone, the highest achievable plasma concentrations
(Cmax) in patients are in the single digit micromolar range [49]. While tissue levels in the central
nervous system and retina are in the low nanomolar range [41,50], the highest concentrations were
detected in the liver (~2 µM in rats; ~10 µM in dogs) [41]. However, these concentrations are
only present for short periods of time (minutes to a few hours depending on the organism) due to
the high rate of hepatic metabolism [26,50]. While our test compounds show significantly higher
metabolic stability compared to idebenone [30], their structural similarity and solubility characteristics
could indicate similar Cmax values in vivo. For idebenone, detailed toxicity data is available from a
large range of patients [18,26,27,51]. Despite the in vitro toxicity observed in the present study for
concentrations above 5 µM (Table 2 and Tables S1–S8), idebenone is extremely well tolerated up to
concentrations of 2250 mg/patient/day with the most common adverse events described as reversible
intestinal disturbances [26]. Hence, the observed toxicities for the test compounds in this study,
even if higher than idebenone, cannot be interpreted as evidence for systemic toxicities at therapeutic
doses. Nevertheless, the increased in vitro metabolic stability of our test compounds compared to
idebenone could increase area under the curve (AUC) values [30] while altered chemical structures
and solubilities could influence ADME characteristics. This highlights that the present study explored
the concentrations from which toxicity can be expected and requires future pharmacokinetic studies of
selected compounds in vivo to establish their safety margins.
Based on the current data and unpublished and ongoing studies, future studies will
investigate the suitability of the most promising compounds to counteract mitochondrial dysfunction-
induced pathologies.
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4. Materials and Methods
4.1. Chemicals and Reagents
Idebenone was provided by Santhera Pharmaceuticals (Pratteln, Basel-Landschaft, Switzerland)
as a reference compound. The novel naphthoquinone derivatives 1–11 were synthesized as described
previously [29]. Dimethylsulfoxide (DMSO), Dulbecco Modified Eagle Medium (DMEM, D5523),
sodium bicarbonate (NaHCO3), 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES),
1,4-dithiothreitol (DTT), magnesium chloride (MgCl2), bovine serum albumin (BSA), Triton X-100,
paraformaldehyde (PFA), Tween-20, rat tail collagen, sodium hydroxide (NaOH), propidium iodide (PI),
poly-L-lysine, menadione, 4′,6-diamidino-2-phenylindole (DAPI), noble agar, and resazurin sodium salt
were purchased from Sigma-Aldrich (Ryde, NSW, Australia). Trypsin, ethylenediaminetetraacetic acid
(EDTA), phosphate-buffered saline (PBS) tablets, Hanks Balanced Salt Solution (HBSS), MitoSOX Red,
Hoechst 33342, Coomassie Brilliant Blue, and goat anti-mouse Alexa Fluor 488 secondary antibody
(A-11029) were obtained from Thermo Fisher Scientific (Scoresby, VIC, Australia). Foetal bovine
serum (FBS) was obtained from SAFC Biosciences (Brooklyn, VIC, Australia). WST-1 Assay Kit
and 2-amino-1-methyl-6-phenylimidazo[4-b]pyridine (PhIP) were obtained from Cayman Chemical
(Redfern, NSW, Australia). DC Protein Assay Kit was obtained from Bio-Rad Laboratories (Gladesville,
NSW, Australia). D-luciferin, luciferase, and MultiTox-Fluor Multiplex Cytotoxicity Assay Kit were
obtained from Promega (Alexandria, NSW, Australia). Mouse monoclonal anti-phospho-Histone
H2AX (Ser139) antibody (JBW301) was obtained from Merck (Kilsyth, VIC, Australia). Methanol and
acetic acid were obtained from VWR (Tingalpa, QLD, Australia). Cell culture plastics were obtained
from Corning (Mulgrave, VIC, Australia), if not stated otherwise.
For all assays, stock solutions (100 mM in DMSO) of reference and test compounds were prepared
as single use aliquots and stored at −20 ◦C until used. DMEM was prepared according to the
manufacturer’s instructions, sterilized by filtration using 0.22 µm bottle top filters, supplemented with
FBS (10%), NaHCO3 (3.7 g/L), and stored at 4 ◦C.
4.2. Cell Culture
Cryopreserved HepG2 cells (HB-8065, ATCC, Noble Park North, VIC, Australia) were passaged
after thawing for at least 2–3 weeks to reach steady cumulative growth rates before being used for
the experiments. The cells were routinely cultured in 5 mL DMEM (95% humidified air, 5% CO2,
37 ◦C) in cell culture flasks (25 cm2, 0.2 µm vent cap). The cells were passaged twice weekly when
reaching ~75% confluency. Cell suspensions were generated by trypsinization (1×wash with 5 mL PBS,
1 × 0.5 mL EDTA (0.5 mM, pH 8), 1 × 0.5 mL trypsin (0.25%, 3.5 min), and seeded into new T25 flasks
at 8 × 104 cells/cm2.
4.3. Multiplex Detection of NAD(P)H, ATP, and Protein Levels
The multiplex detection of NAD(P)H synthesis (absorption, 450 nm), ATP (luminescence) and
protein levels (absorption, 750 nm) from individual wells was used to increase throughput and quality
of results. No statistically significant differences were observed over a range of concentrations with or
without NAD(P)H measurement prior to the quantitation of ATP and protein content from cell lysates
(Figure S1). Briefly, 2 × 104 cells were seeded in 100 µL DMEM per well in transparent 96-well plates
and left to adhere overnight. Subsequently, cells were treated with test compounds for 24 h (0–200 µM
in 25 µL DMEM). After incubation with 5 µL WST-1 reagent for 1 h, absorption was measured using a
plate reader (Multiskan Go, Thermo Fisher Scientific, Scoresby, VIC, Australia). After media removal,
cells were washed twice with 110 µL PBS and permeabilized for 10 min (0.5% Triton X-100/PBS,
40 µL) at room temperature. Cell lysates (10 µL) were mixed with reaction buffer (300 µM d-luciferin,
5 µg/mL luciferase, 25 mM HEPES, 75 µM DTT, 6.25 mM MgCl2, 625 µM EDTA, 1 mg/mL BSA in
PBS, pH 7.4; 90 µL) in white 96-well plates, followed by immediate measurement of luminescence
using a plate reader (Fluoroskan Ascent, Thermo Fisher Scientific, Scoresby, VIC, Australia). Lastly,
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protein contents from cell lysates (5 µL) were quantified using the DC Protein Assay as recommended
by the manufacturer. Absorption and relative luminescence units (RLU) were standardized on the
non-treated control cells (100%). A standard curve using BSA (0–2 mg/mL) was used for protein
quantitation, and protein levels were standardized on the non-treated control (100%). Data was
expressed as mean ± standard error of the mean (SEM) from independent experiments with 6 parallel
wells per experiment.
4.4. Propidium Iodide Incorporation
Cell membrane integrity was assessed using the non-cell membrane permeable dye propidium
iodide (PI). For this purpose, 1 × 104 cells were seeded in 100 µL DMEM per well in 384-well plates
(781091, µClear, Greiner, Ryde, NSW, Australia) and left to adhere overnight. Subsequently, the cells
were treated with test compounds for 24 h (0–200 µM in 50 µL DMEM). After media removal, the
cells were stained with PI solution for 30 min (5 µM in 50 µL PBS), before PI fluorescence (Ex/Em
545/600 nm) was quantified using a plate reader (Fluoroskan Ascent, Thermo Fisher Scientific, Scoresby,
VIC, Australia). RFUs were standardized on the non-treated control and expressed as fold-induction.
Data represented the mean± SEM from 3 independent experiments with 4 parallel wells per experiment.
4.5. Multi-Tox Fluor Kit
Following exposure to test compounds, two different toxicity parameters were measured using
the MultiTox-Fluor Kit according to the manufacturer’s instructions. For this purpose, 5 × 103 cells
were seeded in 100 µL DMEM per well in black 384-well plates (781091, µClear, Greiner, Ryde, NSW,
Australia) and left to adhere overnight. Subsequently, the cells were treated with test compounds for
24 h (0–200 µM in 25 µL DMEM). After incubation with the protease substrate mix for 1 h (permeable
GF-AFC and non-permeable bis-AAF-R110, 25 µL), fluorescence for GF-AFC (Ex/Em 400/505 nm)
and bis-AAF-R110 (Ex/Em 485/520 nm) were measured, respectively, using a multimode plate reader
(Tecan Spark 20M, Tecan, Port Melbourne, VIC, Australia). RFUs were standardized on the non-treated
control (100%) and expressed as mean ± SEM from 3 independent experiments with 3 parallel wells
per experiment.
4.6. MitoSOX
To measure mitochondrial superoxide production, 384-well plates (781091, µClear, Greiner, Ryde,
NSW, Australia) were coated with poly-L-lysine for 45 min (1:20 in HBSS, pH 7.4, 50 µL/well) before
9 × 103 cells were seeded in 50 µL DMEM per well, left to adhere for 3 h, and loaded with MitoSOX
Red (1 µM) and Hoechst 33342 (2 µg/mL in HBSS + 1% BSA, 30 µL/well) for 30 min (Figure S2).
After treatment with test compounds for 30 min (0–200 µM in HBSS + 1% BSA, 50 µL/well), fluorescence
(Ex/Em 355/600 nm) was quantified using a plate reader (Fluoroskan Ascent, Thermo Fisher Scientific,
Scoresby, VIC, Australia). Antimycin A was used as a positive control [31]. RFUs were standardized
on the non-treated control and expressed as fold-induction. Data represented the mean ± SEM from
3 independent experiments with 8 eight parallel wells per experiment.
4.7. Colony Formation Assay
2.5 × 103 cells were seeded in 2 mL DMEM per well in 6-well plates and left to adhere overnight.
Subsequently, cells were treated with test compounds for 14 days (0–100 µM). After media removal,
the colonies were fixed for 10 min (4% PFA/PBS, 2 mL/well), stained for 10 min (1% Coomassie Brilliant
Blue in 50% methanol and 10% acetic acid, 2 mL/well), before the colonies (>50 cells) were counted
under a light microscope. Colony numbers were standardized on the non-treated control (100%) and
expressed as mean ± SEM from 3 independent experiments with 4 four parallel wells per experiment.
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4.8. Assessment of Changes in Nuclear Morphology
To quantitate nuclear morphology, 384-well plates (781091, µClear, Greiner, Ryde, NSW, Australia)
were coated with rat tail collagen for 45 min (1:20 in HBSS, pH 7.4, 50 µL/well) before 1 × 104 cells
were seeded in 100 µL DMEM per well and left to adhere overnight. After treatment with test
compounds for 24 h (100 µM in 50 µL HBSS), fixation for 10 min (4% PFA/PBS, 50 µL/well) and
permeabilization for 10 min (0.5% Triton X-100/PBS, 50 µL/well), the cells were stained with DAPI
for 2 min (1:10,000 in 0.1% Tween-20/PBS, 15 µL/well). After washing three times for 5 min (PBST,
50 µL/well), cells were stored in PBS (50 µL) for high content imaging using an IN Cell 2200 analyser
(10 × magnification, GE Healthcare, Rydalmere, NSW, Australia). Morphological changes (area
and intensity) were automatically quantified for each individual nucleus. Images acquired from
4 wells with 2 images each were automatically analysed using IN Carta image analysis software
(GE Healthcare, Rydalmere, NSW, Australia). Nuclear intensity was standardized on the average
intensity of non-treated control nuclei and expressed as fold-change. Data represented the mean ± SEM
of quadruplicates and ~1000 cells were analysed per treatment.
4.9. Assessment of DNA Damage
To assess DNA damage, 5 × 103 cells were seeded in 100 µL serum-free DMEM per well in
384-well plates (781091, µClear, Greiner, Ryde, NSW, Australia) pre-coated with rat tail collagen
as described above and left to adhere overnight. The cells were treated with test compounds
for 4 h (0–40 µM in 100 µL HBSS/well) while menadione was used as a positive control [32].
After fixation (50 µL) and permeabilization (50 µL) as described above, unspecific antibody binding
was blocked for 1 h (5% FBS + 5% BSA in PBS, 50 µL/well) before the samples were exposed to
mouse monoclonal anti-phospho-Histone H2AX (Ser139) antibody overnight (1:1000 in blocking buffer,
15 µL/well). After exposure to goat anti-mouse Alexa Fluor 488 secondary antibody for 1 h (1:10,000
in PBST, 15 µL/well), nuclei were counterstained using DAPI and stored for imaging and analysis as
described above. The average numbers of γ-H2AX-positive cells were automatically quantified for all
acquired images using IN Carta image analysis software (GE Healthcare, Rydalmere, NSW, Australia).
Results were standardized on the non-treated control and expressed as fold-change. Data represented
the mean ± SEM of quadruplicate images from 3 independent assays. At least 1000 cells were analysed
per treatment.
4.10. Agar Invasion Assay
To further investigate if the test compounds can induce mutations in cells at previously tested
concentrations (10–40 µM), the agar invasion assay in 384-well format (781091, µClear, Greiner, Ryde,
NSW, Australia) was performed as previously described [33]. PhIP was used as a positive control [35].
Cell numbers and incubation times were optimized for PhIP and used for all the test compounds.
Two hundred cells were seeded in 50 µL DMEM (0.4% agar supplemented) per well in 384-well plates
pre-coated with solidified agar (0.6%, 10 µL). The plates were left to solidify for 1 h at room temperature
and incubated overnight at 37◦C before cells were treated for 21 days with reference and test compounds
(10–40 µM in 15 µL DMEM/well). Subsequently, the cells were stained with resazurin for 4 h (440 µM
in 7 µL PBS/well) [34] before fluorescence (Ex/Em 545/600 nm) was quantified using a plate reader
(Fluoroskan Ascent, Thermo Fisher Scientific, Scoresby, VIC, Australia). RFUs were standardized
on the non-treated control and expressed as fold-induction. Data represented the mean ± SEM from
3 independent experiments with 3 parallel wells per experiment.
4.11. Statistical Analysis
Using GraphPad Prism (version 8.2.1, San Diego, CA, USA), one- or two-way ANOVA followed
by Dunnett’s multiple comparison post-test was performed to compare between compounds or
concentrations: *** p < 0.001, ** p < 0.002, * p < 0.033, otherwise non-significant; non-linear regressions
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were generated and half maximal inhibitory concentrations (IC50) were automatically calculated by
the software.
5. Conclusions
This study characterized the in vitro toxicity of the most promising cytoprotective and
mito-protective short-chain naphthoquinones [29,30]. The multiplex detection of compatible assays
described in this study provides a convenient, cost-effective, and rapid approach to increase throughput.
Overall, the test compounds, with some exceptions, showed largely comparable results between
different assays. However, standard assays/dyes appeared to be associated with significantly
higher sensitivity compared to commercially available kits. Compared to the other test compounds,
the L-phenylalanine derivative 4 showed the most promising safety profile, with lower metabolic
toxicity, lower effects on membrane integrity, lower long-term toxicity, as well as an absence of
mitochondrial toxicity, pyknosis, DNA damage, or transformation potential. Our results highlight the
importance of using a set of independent assays to assess distinct toxicity profiles to characterize a
class of compounds. Importantly, this study increased our understanding of the comparative toxicities
of the range of test compounds and supports the development of the most promising short-chain
naphthoquinone(s) towards their clinical use.
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